Intractable in Stent Thrombosis in Malignant Superior Vena Cava Syndrome.
- Author:
Sang Ho LEE
1
;
Chang Woo SHIM
;
Ho Seok CHI
;
Hye In LEE
;
Do Il CHOI
;
Heung Tae KIM
;
Hyun Beom KIM
;
In Joon LEE
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, National Cancer Center, Goyang, Korea. 63023@ncc.re.kr
- Publication Type:Case Report
- Keywords:
Anticoagulation;
Endovascular treatment;
Superior vena cava syndrome
- MeSH:
Aged;
Angioplasty;
Carcinoma, Non-Small-Cell Lung;
Heparin, Low-Molecular-Weight;
Humans;
Neoplasm Metastasis;
Recurrence;
Rivaroxaban;
Stents*;
Superior Vena Cava Syndrome*;
Thrombosis*;
Vena Cava, Superior*;
Venous Thrombosis;
Warfarin
- From:Keimyung Medical Journal
2016;35(1):73-78
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Endovascular treatment (EVT) including angioplasty and stenting is an effective treatment for superior vena cava (SVC) syndrome. Recurrence of SVC syndrome is mainly caused by tumor progression and occurs in around 20% after EVT, but sometimes venous thrombosis within stent accounts for recurrence of SVC syndrome. Anticoagulation after EVT is still a controversial issue. In our case, a 73-year-old man with SVC syndrome caused by mediastinal metastasis from non-small cell lung cancer underwent endovascular stent followed by anticoagulation with low molecular weight heparin (LMWH), but symptomatic progression due to in-stent thrombosis necessitated the second procedure after two weeks. A total of 4 sessions of endovascular stent and anticoagulation with LMWH, warfarin and rivaroxaban did not induce durable resolution of in-stent thrombosis. Our case suggests refractory in-stent thrombosis could develop despite of anticoagulation after endovascular stent for SVC syndrome.
